Search

Abstract Ingestible electronics have the capacity to transform our ability to effectively diagnose and potentially treat a broad set of conditions. Current applications could be significantly enhanced by addressing poor electrode-tissue contact, lack of navigation, short dwell time, and limited battery life. Here we report the development of an ingestible, battery-free, and tissue-adhering robotic interface (IngRI) for non-invasive and chronic electrostimulation of the gut, which addresses challenges associated with contact, navigation, retention, and powering (C-N-R-P) faced by existing ingestibles. We show that near-field inductive coupling operating near 13.56 MHz was sufficient to power and modulate the IngRI to deliver therapeutically relevant electrostimulation, which can be further enhanced by a bio-inspired, hydrogel-enabled adhesive interface. In swine models, we demonstrated the electrical interaction of IngRI with the gastric mucosa by recording conductive signaling from the subcutaneous space. We further observed changes in plasma ghrelin levels, the “hunger hormone,” while IngRI was activated in vivo, demonstrating its clinical potential in regulating appetite and treating other endocrine conditions. The results of this study suggest that concepts inspired by soft and wireless skin-interfacing electronic devices can be applied to ingestible electronics with potential clinical applications for evaluating and treating gastrointestinal conditions.

Abstract Diabetic wounds, characterized by complex pathogenesis and high infection rates, pose significant challenges in treatment due to prolonged recovery times and high recurrence rates, often leading to severe complications such as amputation and death. Traditional dry dressing treatments fail to address the unique microenvironment of diabetic wounds and tend to cause secondary damage due to frequent replacement. In this study, an electronic‐embedding, drug‐loading hydrogel bioelectronics is reported for accelerating diabetic wound healing using a combination of programmable pharmaceutical and electrostimulative approaches. Encapsulated in stretchable and biocompatible materials, this device is capable of multiple drug refilling and accelerated drug release modulated by on‐board electronics. In vivo experiments on diabetic model rats confirm the device's effectiveness in promoting wound healing. This innovative approach implies the potential for improving diabetic wound management using a combination of physical, material, and pharmaceutical interventions.

Transition metal sulfides have garnered increasing attention for their role in persulfate activation, a crucial process in environmental remediation. However, the function of metal sulfides without reversible valence changes, such as ZnS, remains largely unexplored in this context. Here we report ZnS-embedded porous carbon (ZnS-C), synthesized through the pyrolysis of Zn-MOF-74 and dibenzyl disulfide. ZnS-C demonstrates remarkable activity in activating peroxydisulfate (PDS) across a wide pH range, enabling the efficient mineralization removal of bisphenol A (BPA). Through electrochemical investigation and theoretical simulations of charge density distributions, we unveil that the electron transfer from BPA to PDS mediated by the ZnS-C catalyst governs the reaction. This study, both in theory and experiment, demonstrates metal sulfide as electron pump that enhances electron transfer efficiency in PDS activation. These findings redefine the role of metal sulfide catalysts, shedding new light on their potential for regulating reaction pathways in PDS activation processes.

In order to analyze the application effect of oseltamivir and zanamivir in severe type-A H1N1 flue and construct the autoregressive integrated moving average (ARIMA) mathematical model of epidemiology of the disease, 118 cases of critical patients with H1N1 flu were divided into experimental group and the control group. The experimental group was treated with oseltamivir, while the control group was treated with zanamivir. The data of flu patients in 2010–2018 were collected to construct an ARIMA mathematical model and to predict the proportion of HINI diagnoses in 2019. And the onset time of the abatement of fever, clearance time of the fever, symptom scores, history of this disease, syndromes and effectiveness, as well as the adverse events after treatment were all recorded. The results showed that there were 71 cases (60.12%) had exposure history with patients of H1N1 flu, 31 cases (25.91%) had a close contact history with those patients, and 6 cases (4.92%) had already got a flu vaccination; the patient had the highest cough rate (84.15%) in respiratory symptoms, the highest fever rate (94.41%) in systemic toxemic symptoms, and the highest nausea rate (35.27%) in gastrointestinal symptoms; the prediction results of ARIMA mathematical model in February, March, April, May, July, August, October, November, and December were not significantly different from the real results (P > 0.05), and were significantly different from the real results in in January, June, and September (P 0.05), and the clearance time of the fever was lower than that in the control group (P